| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Climb Bio, Inc. | SVP, Finance & CAO | Restricted Stock Units | 20K | $40.4K | $2.02 | Mar 18, 2025 | Direct |
| Climb Bio, Inc. | SVP, Finance & CAO | Common Stock | 15.1K | $19.8K | $1.31 | Mar 20, 2025 | Direct |
| Climb Bio, Inc. | SVP, Finance & CAO | Stock Option (Right to Buy) | 100K | Jan 13, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | Mar 18, 2025 | 3 | -$1.57K | 4 | Mar 20, 2025 | SVP, Finance & CAO |
| CLYM | Climb Bio, Inc. | Jan 13, 2025 | 1 | $0 | 4 | Jan 15, 2025 | SVP, Finance and CAO |
| CLYM | Climb Bio, Inc. | Dec 18, 2024 | 3 | -$2.49K | 4 | Dec 20, 2024 | CHIEF ACCOUNTING OFFICER |
| ELYM | Eliem Therapeutics, Inc. | Sep 18, 2024 | 4 | -$9.74K | 4 | Sep 20, 2024 | CHIEF ACCOUNTING OFFICER |
| ELYM | Eliem Therapeutics, Inc. | Jun 18, 2024 | 3 | -$8.98K | 4 | Jun 21, 2024 | CHIEF ACCOUNTING OFFICER |
| ELYM | Eliem Therapeutics, Inc. | Mar 18, 2024 | 1 | $0 | 4 | Mar 20, 2024 | CHIEF ACCOUNTING OFFICER |
| ELYM | Eliem Therapeutics, Inc. | Mar 13, 2023 | 0 | $0 | 3 | Mar 21, 2023 | Chief Accounting Officer |